Tests dual bronchodilation effects on breathing and heart in newly diagnosed COPD
Observes how initial dual bronchodilator treatment affects breathing, heart and quality of life in COPD.
Plain-language title generated from the registry record
Registry title: Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Kaunas, LithuaniaSee the site
Where in Lithuania
- Lithuanian University of Health SciencesKaunas, LithuaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lithuanian University of Health Sciences
- Trial code
- NCT06072690
- Record updated
- 2 April 2026
- Original description
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g. bronchitis, bronchiolitis) and/or alveoli (emphysema) that lead to persistent, often progressive, airflow obstruction.Read full original descriptionShow less
The Impact of Dual Bronchodilation on Respiratory and Cardiovascular Systems in Patients With Newly Diagnosed Moderate-to-severe Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a lung condition characterized by chronic respiratory symptoms (dyspnoea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (e.g. bronchitis, bronchiolitis) and/or alveoli (emphysema) that lead to persistent, often progressive, airflow obstruction.
It is a major cause of disability and death worldwide. Moreover, people with COPD often have cardiovascular diseases (CVDs) that are associated with increased risk for hospitalization and prolonged stay as well as all-cause and CVD-related mortality. Nevertheless, CVDs in patients with COPD are tend to be underestimated in clinical practice. Mechanisms that define the relation between COPD and cardiovascular morbidity include lung hyperinflation, hypoxia, pulmonary hypertension, systemic inflammation and oxidative stress, exacerbation, shared risk factors and COPD phenotypes. In the past years, some authors have announced that COPD treatment with dual bronchodilation may not only improve pulmonary function and quality of life, but also have a positive effect on cardiac function. However, there is a lack of studies with treatment-naïve patients that would describe the initial effect of dual bronchodilation on respiratory and cardiovascular systems. In this study we aimed to evaluate the effect of initial dual bronchodilation on the quality of life, respiratory and cardiovascular systems in patients with newly-diagnosed chronic obstructive pulmonary disease.
Inclusion: Aged 40 years and older; Smoking index of 10 pack-years and more; Newly diagnosed chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 30-79 percent of predicted and forced expiratory volume in 1 second to forced vital capacity ratio (FEV1/FVC) less than 70 percent of predicted.
Exclusion: Present or previously treated lung cancer; Previously diagnosed asthma; Treatment with systemic glucocorticoids; Active lung infection; Diagnosed interstitial lung disease; Diagnosed chronic hypercapnic respiratory failure; Unstable ischaemic heart disease; Present cardiac arrhythmias; Uncontrolled arterial hypertension; Dementia and other mental states that determine patient's inability to consent; Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion; Alpha-1 antitrypsin deficiency; Pregnancy.